Effectiveness of additional ultrathin bronchoscopy for peripheral pulmonary lesions to which a radial endobronchial ultrasound (EBUS) probe cannot be advanced during bronchoscopy

Effectiveness of additional ultrathin bronchoscopy for peripheral pulmonary lesions to which a radial endobronchial ultrasound (EBUS) probe cannot be advanced during bronchoscopy - Effectiveness of ultrathin bronchoscopy added to bronchoscopy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024306

Enrollment

260

Registered

2016-10-06

Start date

2016-10-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign or malignant pulmonary lesions

Interventions

EBUS-TBB-VBN with an ultrathin bronchoscope

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with a peripheral pulmonary lesion < 30 mm in size who need to undergo diagnostic bronchoscopy 2. 20 years old or older 3. Informed consent

Exclusion criteria

Exclusion criteria: 1. Serious concomitant medical illness 2. Central pulmonary lesions 3. Lesion located within the inner third ellipse from the hilum on chest CT 4. Re-examination following prior failure in this trial 5. Case with pure ground glass nodule 6. Patients needing to undergo bronchoscopic procedures for non-target lesion in the same setting 7. Diffuse pulmonary lesions 8. Pregnancy 9. Bleeding tendency 10. Other clinical difficulties in this trial

Design outcomes

Primary

Measure	Time frame
1. Diagnostic yield of histology specimens	—

Secondary

Measure	Time frame
1. Diagnostic yield: benign or malignant 2. Diagnostic yield according to lesion size: < 20 mm or > 20 mm 3. Diagnostic yield according to lesion location relative to the hilum 4. Diagnostic yield according to lesion location in the bronchopulmonary segment 5. Visibility with EBUS 6. Diagnostic yield according to presence of the air bronchus sign 7. Diagnostic yield according to lesion appearance on CT: solid or ground glass nodule 8. Level of bronchus reached with ultrathin bronchoscope 9. Frequency of reaching the lesion with ultrathin bronchoscope 10. Time required for examination procedure 11. Incidence of adverse effects	—

Measure

Time frame

1. Diagnostic yield: benign or malignant 2. Diagnostic yield according to lesion size: < 20 mm or > 20 mm 3. Diagnostic yield according to lesion location relative to the hilum 4. Diagnostic yield according to lesion location in the bronchopulmonary segment 5. Visibility with EBUS 6. Diagnostic yield according to presence of the air bronchus sign 7. Diagnostic yield according to lesion appearance on CT: solid or ground glass nodule 8. Level of bronchus reached with ultrathin bronchoscope 9. Frequency of reaching the lesion with ultrathin bronchoscope 10. Time required for examination procedure 11. Incidence of adverse effects

—

Countries

Japan

Contacts

Public ContactMasahide Oki

Nagoya Medical Center Department of Respiratory Medicine

masahideo@gmail.com052-951-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026